StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $7.33 | $7.68 | +4.77% | 1.0M |
| 05-12 | $7.67 | $7.72 | +0.65% | 1.0M |
| 05-13 | $7.50 | $7.38 | -1.60% | 1.6M |
| 05-14 | $7.50 | $7.63 | +1.73% | 1.5M |
| 05-15 | $7.43 | $6.92 | -6.86% | 2.0M |
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Each factor shows SLDB's percentile within the scored universe — observational ranking, not a recommendation.
| Metric | Q3 2026 (Est.) Expected 2026-08-10 | Annual 2022 2022-12-31 | Annual 2021 2021-12-31 | Annual 2020 2020-12-31 | Q3 2020 2020-09-30 |
|---|---|---|---|---|---|
Revenue | $0.00 | $8.09M | $13.62M | $0.00 | $0.00 |
Operating Income | Not available | $-106.45M | $-72.25M | $-88.41M | $-67.06M |
Net Income | Not available | $-85.98M | $-72.19M | $-88.29M | $-66.93M |
EPS (Diluted) | $-0.41 | $-10.10 | $-10.14 | $-25.50 | Not available |
Total Assets | Not available | $260.25M | $232.38M | $171.17M | $40.52M |
Total Liabilities | Not available | $48.59M | $24.17M | $39.08M | $18.29M |
Cash & Equivalents | Not available | $155.38M | $119.14M | $154.74M | $24.80M |
Free Cash Flow OCF − CapEx | Not available | $-100.99M | $-79.05M | $-57.50M | $-58.74M |
Shares Outstanding | Not available | 19.56M | 7.36M | 84.89M | 46.18M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
SLDB is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1138-name primary list.
DNA analysis is not available for this ticker.